Novartis COVID-19 Response Fund provides support to healthcare workers and communities

Novartis is making rapid progress in distributing the allocated USD 20 million of the Novartis COVID-19 Response Fund, announced mid-March, to impacted countries around the world. The fund aims to support public health initiatives designed to help communities manage the challenges posed by the pandemic, such as programs to strengthen healthcare infrastructure, digital platforms for data collection or dissemination of important public health information, and community health programs.

Read the full featured news [2]

Novartis US Foundation establishes USD $5 million US COVID-19 Community Response Fund

In response to the COVID-19 pandemic, the Novartis US Foundation has established the US COVID-19 Community Response Fund to support local initiatives and communities in the US impacted by the outbreak. The fund will provide up to USD $5 million over a one-year period for immediate response and recovery efforts related to the pandemic.

Read the full Novartis US media release [3]

Novartis announces first European donation of hydroxychloroquine to Switzerland

Rotkreuz, April 3, 2020 – Today, Novartis, announced the donation of a substantial amount of hydroxychloroquine to treat hospitalized COVID-19 patients within Switzerland. The aim of the donation is to enable patients to access a potential treatment while also advancing clinical research in the fight against COVID-19. Switzerland is the second country in the world after
the USA, and the first in Europe, to receive a donation of this medication. The Swiss authorities are responsible for distributing the drug to hospitals.

Read the full statement [4]

Read the German [5] and French [6] media releases

April 02, 2020

Novartis announces plan to initiate clinical study of Jakavi® in severe COVID-19 patients and establish international compassionate use program

Basel, April 2, 2020 — Novartis today announced plans to initiate a Phase III clinical trial in collaboration with Incyte to evaluate the use of Jakavi® (ruxolitinib) for treatment of a type of severe immune overreaction called cytokine storm that can lead to life-threatening respiratory complications in patients with COVID-19¹-³.

Read the full media release [7]

March 30, 2020

Novartis donates 20,000 doses of hydroxychloroquine for COVID-19 PEP clinical trial????

East Hanover, NJ, March 30, 2020 – Novartis announced today that it is donating 20,000 doses of hydroxychloroquine to the University of Washington for a COVID-19 PEP clinical trial. Sandoz, the company’s generics and biosimilars division, is facilitating the donation.

Read the full Sandoz US media release [8]

March 30, 2020

Novartis donation: Consignment of 30 million hydroxychloroquine tablets ships to US Department of Health and Human Services
Princeton - Novartis announced today that Sandoz, its generics and biosimilars division, has started to ship a consignment of 30 million doses of hydroxychloroquine tablets to the US Department of Health and Human Services (HHS) for immediate use in controlled clinical studies. The study will evaluate the medicine’s effectiveness in people who have tested positive for COVID-19. The shipment is part of the previously announced global Novartis donation of 130 million tablets in total to be distributed across a variety of clinical trials and stakeholders internationally.

Read the full Sandoz media release [9]

March 27, 2020

Novartis announces further steps to protect and support its associates during the COVID-19 Pandemic

As the coronavirus (COVID-19) situation continues to evolve, our primary concern at Novartis remains the health and safety of our associates and patients globally. With that in mind, this week Novartis announced a range of additional measures to protect and support our associates around the world.

Read the full statement [10]

March 26, 2020

Novartis and life sciences companies commit expertise and assets to the fight against COVID-19 pandemic alongside Bill & Melinda Gates Foundation

Basel, March 26, 2020 — Today, Novartis and a consortium of life sciences companies announced an important collaboration to accelerate the development, manufacture and delivery of vaccines, diagnostics, and treatments for COVID-19 in response to the pandemic. The industry brings a range of assets, resources, and expertise needed to identify effective and scalable solutions to the pandemic that is affecting billions worldwide. Effects on health systems, economies, and livelihoods are significant, and effective response requires an unprecedented collaboration across government, academia, private sector, and philanthropy.

Read the full media release [11]

March 20, 2020
Novartis commits to donate up to 130 million doses of hydroxychloroquine to support the global COVID-19 pandemic response

Basel, March 20, 2020 - Novartis announced today its commitment to donate up to 130 million doses of generic hydroxychloroquine to support the global COVID-19 pandemic response. Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19. Novartis is supporting ongoing clinical trial efforts, and will evaluate needs for additional clinical trials.

Read the full media release [12]

March 17, 2020

Novartis announces broad range of initiatives to respond to COVID-19 Pandemic and creates USD 20 million global fund to support impacted communities

Basel, March 17, 2020 - Vas Narasimhan, CEO of Novartis, said: “We are dealing with an extraordinary and unprecedented public health crisis that requires an incredible level of involvement and collaboration across government, society and business. As a medicines company present in over 140 countries, we are stepping in to provide additional financial support to critical community or national programs that can help address urgent public health needs resulting from the COVID-19 pandemic. Recognizing the power of working together as an industry, we are also bringing the talent and capabilities of our industry-leading R&D organization to two leading and important collaborative R&D initiatives.”

Read the full media release [13]

March 13, 2020

Novartis coronavirus update (remote working, business travel restrictions)

As the coronavirus (COVID-19) continues to spread globally, our primary concern at Novartis remains the health and safety of our associates and patients globally, and it is important that we protect them.

Read the full statement [14]

March 11, 2020

Novartis coronavirus update (supply chain, response)
As Novartis continues to closely monitor the coronavirus situation, our primary concern is the health and safety of our associates and patients globally. We will continue to deliver our medicines to patients around the world and we do not anticipate supply chain disruption at this time.

Read the full statement [15]


Links